In conclusion, MyD88 overexpression was associated with carcinogenesis and tumor progression of EOC and with an increased risk of metastasis and worse survival, and the identification of MyD88 expression as determined by immunohistochemistry is a useful prognostic factor in EOC. Here, MYD88 is linked to neoplasm.